ABTECT - Maintenance
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of
ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with
moderately to severely active ulcerative colitis who have inadequate response, no respo...
Age: 16 years - 66+
Gender: All
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and
safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with
moderately to severely active ulcerative colitis who have inadequate response, no respon...
Age: 16 years - 66+
Gender: All
Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis
The objective of this study is to assess the efficacy of hydroxychloroquine (HCQ) when
combined with Mesalamine in reducing clinical and histologic disease activity in patients who
have active mild to severe Ulcerative Colitis (UC) and also to assess the immunologic...
Age: 18 years - 66+
Gender: All
A Long-term Extension Study of Ustekinumab in Pediatric Participants
The purpose of this study is to collect long-term safety data of subcutaneous (SC)
ustekinumab
Age: 2 - 17 years
Gender: All
Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)
The researchers intend to prospectively study the safety, clinical efficacy and microbial
outcomes in patients with recently diagnosed UC with FMT capsule therapy derived from
pre-defined donors. Donors will be specifically screened for Fusobacterium and Sutterella
...
Age: 18 - 75 years
Gender: All
Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)
The researchers intend to prospectively study the safety, clinical efficacy and microbial
outcomes in patients with recently diagnosed UC with FMT capsule therapy derived from
pre-defined donors. Donors will be specifically screened for Fusobacterium and Sutterella
...
Age: 18 - 75 years
Gender: All
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in
pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will
last about 172 weeks and may include up to 44 visits.
Age: 2 - 19 years
Gender: All
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK)
of tofacitinib in pediatric participants with moderately to severely active UC. In the US and
EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of...
Age: 2 - 17 years
Gender: All
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
Crohn's disease (CD) is the major form of inflammatory bowel disease (IBD) affecting adults.
It is a life-long disease characterized by chronic and relapsing inflammation of the
gastrointestinal tract. CD has multiple clinical phenotypes and disease severities that
...
Age: 18 - 30 years
Gender: All
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as
maintenance therapy in participants who completed prior 12-week induction study AMAN
(NCT03518086).
Age: 18 - 80 years
Gender: All
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in
participants with moderately to severely active ulcerative colitis (UC) who have had an
inadequate response to, loss of response, or intolerant to conventional or biologic therapy
f...
Age: 18 - 80 years
Gender: All
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.
Age: 18 - 80 years
Gender: All
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients
(age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical
practice. TARGET-IBD will create a research registry of patients with IBD within academic...
Age: 2 years - 66+
Gender: All
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
The purpose of this observational study is to find the best measures to define how well a
person with eosinophilic disorder is doing. People with EoE, EG, EGE and EC normally undergo
endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Tr...
Age: 3 years - 66+
Gender: All
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in
patients with moderately to severely active UC who are treated as recommended in the product
label.
Age: 18 - 99 years
Gender: All